Pinter A, Green LJ, Selmer J, et al. - Topical treatment of plaque psoriasis with a novel fixed dose combination CAL(calcipotriol)/BDP(betamethasone dipropionate) PAD-cream (based on PAD Technology) provided greater efficacy, superior patient quality of life and equivalent favorable safety, relative to the currently available topical suspension/gel.

• Pooling and analysis of data from two phase 3, multicenter, randomized, investigator-blind, active, and vehicle-controlled trials of patients with psoriasis was done.

• A CAL/BDP cream based on PAD Technology (PAD-cream), an active control (marketed CAL/BDP topical suspension/gel: CAL/BDP TS), and cream vehicle, were applied once daily for 8 weeks.

• Superiority for all efficacy endpoints was shown by the novel CAL/BDP PAD-cream formulation, and it afforded greater PGA treatment success (43.2%) than CAL/BDP TS (31.9%).

• CAL/BDP PAD-cream provided 64.6% mean percent reduction in mPASI, vs 56.4% for CAL/BDP TS, and DLQI 0/1 was achieved by 43.8% in the CAL/BDP PAD-cream group vs 34.2% in the CAL/BDP TS group.

• No adverse drug reaction was reported with a frequency of >1%, related to the CAL/BDP PAD-cream.